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BACKGROUND AND STRATEGY 
The term ‘postmarketing surveillance’ refers to analyses for the purpose of detecting adverse 
drug reactions in data accumulated after a medicinal product has been authorized by a 
regulatory agency [1-3]. The current regulatory process has systematic provisions for 
obtaining important data needed to ensure the safety of novel drugs almost exclusively during 
premarketing testing [4]. However, premarketing trials frequently do not have sufficient 
power to reliably detect important adverse drug reactions [5]. This is because trials are 
usually powered for the intended therapeutic effect, and therefore they are underpowered for 
side effects that are rarer than the therapeutic effects. In addition, registration trials are often 
performed in a relatively healthy subset of patients with the condition of interest, and exclude 
users of co-medication, thereby reducing the likelihood to detect drug-drug interactions [5]. 
Therefore, postmarketing surveillance has been introduced to fill this gap by evaluating the 
safety of medicinal products and to determine unexpected effects occurring after marketing 
authorization. In the last few years there has been an increasing worldwide emphasis on the 
development of improved strategies to evaluate the safety of new drugs in the postmarketing 
phase [6,7] in various fields, including haemophilia.  
Since a large number of novel products for haemophilia treatment have recently been or will 
be licensed soon, such as modified clotting factor concentrates with extended half-life 
(PEGylated or Fc- or Albumin-fusion products) and alternative haemostatic-enhancing drugs 
(anti-TFPI, ALN-AT3 or ACE910), we need to have a systematic approach to postmarketing 
surveillance, in order to monitor their long-term safety.  
Therapeutic effects of drugs need to be studied in randomized trials, since physicians will 
invariably tie prescription of a specific drug to the risk profile of the patient, by factors which 
usually are too subtle to measure and control for. This confounding by indication may distort 
the results. For adverse events, usually few risk factors are known and hence confounding is 
less of a problem, but should still be carefully considered. Since randomized trials are not 
usually feasible to assess side effects, observational studies are the more suitable to assess 
safety. However, it should be kept in mind that confounding with incomparability of groups 
remain the main issues in observational study designs. 
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Observational studies can either be cohort or case-control studies. The guidelines for cohort 
studies, see reporting guidelines as STROBE [8], apply for the study of adverse effects, too: 
an unbiased inception cohort is formed and followed over time. Ideally, all eligible 
individuals in a well-defined region and time window are included from the time of becoming 
eligible and are all followed in a similar way. Deviation of this ideal should be considered for 
its potential to bias, the most important of which is selective inclusion of patients. This results 
in many registers resembling case series rather than an appropriate baseline sample of a 
cohort study. The minimum requirement is that participating centres include consecutive 
patients without selection.  
An efficient alternative to cohort studies is to perform case-control studies, which are 
generally seen as the optimal design to assess adverse drug reactions, since they maximize 
power and efficiency. In this design, new cases of patients with the complication of interest 
are included and compared with patients without. A requisite here is an unbiased database of 
patients with the complication of interest, and an appropriate control group. While 
maximizing power, drawbacks are that only one type of adverse event can be studied and that 
only relative rates can be computed, and not absolute risks. 
When true registers are built as inception cohorts the two designs can both be employed 
within the information base along with powerful mixed forms such as nested case-control 
studies. 
Within the framework of the International Society of Thrombosis and Haemostasis, Scientific 
and Standardization Subcommittee (ISTH/SSC) - Factor VIII, IX and Rare Coagulation 
Disorders -, a working group was appointed to optimize a minimum standardized set of data 
necessary to bring information on safety of new drugs after product registration.  
The ISTH/SSC working Group consists of physicians, representatives of National and 
International registries, epidemiologists, representatives of regulatory agencies and of 
patients organisations (see acknowledgment section). 
The members of this working group collaborated to draft a minimal standardised dataset, 
starting from a critical analysis of the information reported in all available National and 
International databases/registers (American Thrombosis and Hemostasis Network – ATHN - ; 
Canadian Hemophilia Surveillance System - CHESS - ; European Haemophilia Safety 
Surveillance - EUHASS- ; FranceCoag database; PedNet Haemophilia Registry; United 
Kingdom Haemophilia Centres Doctors' Organisation database – UKHCDO). A preliminary 
data collection scheme was submitted first to the regulatory agencies, patient associations 
(World Federation of Hemophilia National Hemophilia Foundation, and European 
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Haemophilia consortium) and then to pharmaceutical industries for collecting their 
suggestions and comments. Then, a core set of information to be collected was consolidated 
as provided in the Supporting Information. 
 
COLLECTION DATASET 
The ISTH/SSC working group has developed an essential and user-friendly data format for 
pharmacovigilance (Supporting Information). All haemophilia patients in a participating 
centre treated for the first time with a new haemostatic product regardless of severity and age, 
should be registered, including previously untreated (PUPs) and treated patients (PTPs) in 
order to monitor accurately the onset of any drug-related adverse events.    
The electronic data collection forms (Supporting information) requires the following 
information, divided in baseline data at entry, and regularly completed follow-up data: 
A. Baseline data  
1. Demographic data: patient identifier, data of birth, country, sex, ethnicity, body weight.  
2. Clinical data: type of haemophilia, baseline clotting factor activity (% or IU/dl), date of 
diagnosis, family history of haemophilia, date of the first bleeding, mutation type. 
3. Treatment data: each concentrate used, treatment regimen, mean dose per kg per year. 
For PUPs and for patients switching product, additional questions should be answered 
in the follow up form. 
B. Follow-up data (at least every 6 months or 1 year)  
4. Treatment data: details on products and regimens to be provided only for PUPs and for 
cases undergoing concentrate switches. 
5. Adverse events notifications: all adverse events or the absence thereof should be 
assessed for a long period of time (at least for 3-5 years, preferably for the entire life of 
patients) including the occurrence of inhibitors, allergic/hypersensitivity reaction, 
death, malignancy, thromboembolic events (arterial, venous and microangiopathic), and 
infections or any other unexpected side effect. Considering that in preclinical studies 
vacuolation in various tissues was observed at high doses after exposure to PEG-
conjugated drug [9-11], the introduction of new molecules will need new monitoring 
methods and as a minimum, renal and hepatic functions should be monitored by an 
annual sampling of peripheral blood (e.g., creatinine, urea, serum transaminase, 
alkaline phosphatase, gamma-Glutamyl transferase, pseudocholinesterase, albumin, 
bilirubin) and urine analysis (e.g. proteinuria, microalbuminuria). Any other type of 
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unusual or unexpected adverse event (e.g. neurologic disorders or behavioral deficits, 
liver, kidney, skin) needs to be recorded for any modified products.  
6. Inhibitor monitoring: PTPs starting a new product should be followed for at least 100 
exposure days (EDs) and assessed at 1, 10-15, 50-75, 100 EDs and then annually, with 
registration of treatment specific information. PTPs with a past history of an inhibitor 
will be a particularly important group to observe. Data to be collected and reported for 
inhibitors developing in PTPs has been described in another statement of this 
ISTH/SSC [12]. 
PUPs should be followed for at least 75 ED and inhibitor testing should be performed at 
1, 5, 10, 20, 30, 50, 75 EDs and then annually.  
The assessment of inhibitor development is based on the EMA guideline on the clinical 
investigation of new FVIII and FIX products [13,14]. A different version was 
developed for PTPs by the SSC of the ISTH considering the ‘biphasic’ nature of the 
inhibitor incidence after FVIII exposure: an early exposure (15, IQR 10–20 EDs) high 
peak ‘epidemic’ rate of up to 30% in PUPs is followed by a lifelong low ‘endemic’ 
incidence of 0.1–0.6% per patient-year [15].    
7. Levels of antibodies against the drug (PEG, Fc, etc) should be reported (when available 
and tested), including when there is a reduced half-life of the drug, even if there are not 
standardised assays available until now 
 
DATA STORAGE AND ANALYSIS 
The ISTH/SSC working group advises that: 
- this system of data collection should be available universally in all Haemophilia Treatment 
Centres so that every patient treated for the first time with a new haemostatic agent is 
registered, and all adverse effects including inhibitor development are recorded over time; 
- all patients, both PUPs and PTPs should be included;  
- the registration of each patient should be recorded at a national level with a unique 
identifier in order to prevent duplication;  
- the unique identified should be implemented also in international databases in order to 
have a harmonised data collection system;  
- data subsets should be shared and analysed at an international level at regular intervals by 
an independent body.  
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CONCLUSION 
The ISTH/SSC working Group has formulated a consensus essential data collection tool in 
order to evaluate any potential side effect related to a new haemostatic product in a 
standardised way to allow cohort and case-control analyses.    
This data collection system has the advantages to be uniform and standardised and collects 
information over extended time periods. It allows pooling of datasets from haemophilia 
treatment centres around the world in order to detect low frequency adverse effects (not 
identified in premarketing clinical trials and not detectable in a single cohort) and eventually 
to link the information to other International databases. This instrument allows also to detect 
new unlabelled adverse events and unanswered questions of long-term safety observation on 
novel products in the entire population or specific subgroups of interest [16].  
This collection system is a common instrument to share information on safety of the products 
internationally and implement and exchange the knowledge on novel drugs to ensure a better 
surveillance for the patients. 
This standardised method of data collection will also allow regulators to have access to real 
life data and identify any unexpected increase in immunogenicity or any unexpected or 
unknown side effect of a new licensed product. 
  
Addendum 
F. Peyvandi wrote the first draft of the manuscript, which was subsequently discussed during 
conference calls among members of the Project Group and adapted according to the 
comments of the co-authors in several rounds. All authors provided input for all versions of 
the manuscript. All authors reviewed and approved the final version of the forms of data 
collection. 
 
Supporting Information 
Additional Supporting Information may be found in the online version of this article: 
Form of data collection. 
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